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Abstract 
Radiomics is the high-throughput extraction and analysis of quantitative image 
features. For non-small cell lung cancer (NSCLC) patients, radiomics can be applied to 
standard of care computed tomography (CT) images to improve tumor diagnosis, 
staging, and response assessment.  
The first objective of this work was to show that CT image features extracted 
from pre-treatment NSCLC tumors could be used to predict tumor shrinkage in 
response to therapy. This is important since tumor shrinkage is an important cancer 
treatment endpoint that is correlated with probability of disease progression and overall 
survival. Accurate prediction of tumor shrinkage could also lead to individually 
customized treatment plans.  
To accomplish this objective, 64 stage NSCLC patients with similar treatments 
were all imaged using the same CT scanner and protocol. Quantitative image features 
were extracted and principal component regression with simulated annealing subset 
selection was used to predict shrinkage. Cross validation and permutation tests were 
used to validate the results. The optimal model gave a strong correlation between the 
observed and predicted shrinkages with    0.81.  
The second objective of this work was to identify sets of NSCLC CT image 
features that are reproducible, non-redundant, and informative across multiple 
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machines. Feature sets with these qualities are needed for NSCLC radiomics models to 
be robust to machine variation and spurious correlation. 
To accomplish this objective, test-retest CT image pairs were obtained from 56 
NSCLC patients imaged on three CT machines from two institutions. For each machine, 
quantitative image features with concordance correlation coefficient values greater than 
0.90 were considered reproducible. Multi-machine reproducible feature sets were 
created by taking the intersection of individual machine reproducible feature sets. 
Redundant features were removed through hierarchical clustering.  
The findings showed that image feature reproducibility and redundancy 
depended on both the CT machine and the CT image type (average cine 4D-CT 
imaging vs. end-exhale cine 4D-CT imaging vs. helical inspiratory breath-hold 3D CT). 
For each image type, a set of cross-machine reproducible, non-redundant, and 
informative image features was identified. Compared to end-exhale 4D-CT and breath-
hold 3D-CT, average 4D-CT derived image features showed superior multi-machine 
reproducibility and are the best candidates for clinical correlation.  
 
 
____________________ 
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Chapter 1: Introduction 
1.1 Background and Significance 
Lung cancer is the leading cause of cancer-related mortality both worldwide and in 
the United States (1). Over 200,000 new lung cancer cases are diagnosed and over 160,000 
people die due to the disease every year in the United States (2).   Non-small cell lung 
cancer (NSCLC) accounts for approximately 85% of these lung cancer cases, and overall 5-
year lung cancer survival is 15% (3). The variation of current incidence rates is primarily 
explained by variations in historical tobacco use (4). Therefore, as a result of decreased 
tobacco consumption, incidence rates in the United States are declining. However, 
worldwide incidence rates are rising rapidly due to increased tobacco use in China and other 
developing nations (5).  
The tumor node metastasis (TNM) staging system is a systematic way of 
representing the spread of lung cancer by assessing tumor size, nodal involvement, and 
metastatic extent (6). Staging information is obtained using thoracic computed tomography 
(CT) and is often augmented by positron emission tomography (PET) which can detect 
metabolically active microscopic disease (7). The three TNM categories can be combined 
(i.e. stage grouped) to give an overall tumor stage which has important implications for 
treatment and prognosis. Stage I lung cancer is present in the lungs only, stage II has 
nearby lymph node involvement, stage III (locally advanced disease) has more distant lymph 
node involvement, and stage IV (advanced disease) has additional organ-system 
involvement. Surgical resection is recommended for stages I and II, and has relatively good 
clinical outcomes.  However, approximately 70% of patients present with stage III or stage IV 
disease (2). Chemotherapy is generally recommended for stage IV patients, and radiation 
with concurrent chemotherapy is recommended for stage III treatment.   
At its core, the TNM staging system is an exclusively anatomically-oriented system 
that does not take advantage of additional data which may be relevant to prognosis and 
treatment, and patients that are assigned the same stage often have large variations in 
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clinical outcome. The addition of information from various non-anatomical sources could help 
reduce this problem. For example, the simple physiological features of patient age and body 
mass index have been shown to improve NSCLC staging (8). Integration of genetic 
information (e.g. single nucleotide polymorphism genotyping) improves the ability to predict 
patient survival (9-11), and serum biomarkers have also shown promise for NSCLC 
recurrence prediction (12). The literature shows that these and other molecular biomarkers 
can be used for indicating etiology, prognosis, and therapy response (13-15). However, 
external validation studies for molecular biomarker studies have largely been unsuccessful, 
and their clinical application seems stunted (16). This could be due to variations in institution 
demographics, sample collection, and/or analysis techniques. Additionally, many solid 
tumors are known to be temporally heterogeneous (i.e.  genotype changes through time) 
and/or spatially heterogeneous (i.e. genotype varies spatially within the tumor). Therefore, a 
biopsy sampling a random spatial sub-region of a tumor at a single time point may not be 
able to accurately reflect true complexity of the tumor (17).  
In light of these complications, CT imaging seems like a viable alternative for probing 
the information content of tumors. CT imaging is readily available, and any additional 
information gleaned from imaging is essentially “free” since it is performed as part of the 
standard of care for lung cancer. Additionally, because of its non-invasive nature, CT 
imaging can be used to achieve high temporal resolution via frequent imaging (17). CT 
imaging also has high spatial resolution which can allow for quantification and assessment of 
intra-tumor spatial heterogeneity (17). This is important since identification of an image 
heterogeneity – treatment response link could be used to further optimize the therapeutic 
ratio of radiation treatments (18).  
Various CT image features can be useful descriptors. In NSCLC, tumors are often 
qualitatively described as spiculated or cavitated, and several groups are working to develop 
a constrained vocabulary for lung tumor CT image annotation (19, 20). Tumors are also 
commonly described by quantitative one-dimensional (Response Evaluation Criteria in Solid 
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Tumors) or two-dimensional (World Health Organization) size measurements. However, the 
nuances of tumor morphology are not well-captured by these two measures, and in some 
cases their changes do no strongly correlate with therapeutic benefit (21, 22). Other 
commonly obtained quantitative image features such as the mean voxel intensity are 
typically simple calculations over the region of interest (ROI) (23). More advanced 
quantitative measures are usually statistical, model, or transform based and reflect variations 
in tumor morphology, heterogeneity, and/or texture (24). Statistics-based image features 
such as the run-length matrix (RLM) and co-occurrence matrix (COM) are based on 
probabilities of voxels occurring in certain combinations (25, 26). Model-based image 
features such as the fractal dimension quantify texture irregularity and roughness (24). 
Transform-based methods such as the wavelet transform are used to quantify textures in the 
frequency space (24). Compared to simple ROI-averaged image features, these more 
advanced features tend to have significantly improved prognostic power (27-30). 
  Inspired by the high-throughput success of the “omics” (genomics, proteomics, 
metabolomics, etc.), the newly created field of radiomics is centered around the high-
throughput extraction of advanced quantitative image features (17). The radiomics 
hypothesis is that these image features are related to a tumor’s underlying genotype and 
phenotype. This was first shown to be true in liver cancer where 28 image features were 
able to reconstruct 78% of the gene expression profile (31). Other studies have shown that 
genomic heterogeneity, treatment resistance, and metastatic probability are each associated 
with tumor image heterogeneity (27, 32). In addition, CT texture analysis can indicate tumor 
invasion and estrogen receptor status in patients with breast cancer, can partition high and 
low grade cerebral gliomas, and can indicate overall survival rates in colorectal cancer (33-
35). In lung cancer, image features have also been used to distinguish between the 
adenocarcinoma and squamous cell carcinoma subtypes of NSCLC (36). The fractal 
dimension of lung tumors has been used to classify pulmonary nodules and also correlates 
with tumor stage (37, 38). NSCLC CT texture analysis by Ganeshan et al. has also 
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discovered image feature associations for tumor stage, metabolism, hypoxia, and 
angiogenesis (39, 40). 
Particularly in NSCLC CT radiomics applications, authors often lament the lack of 
data standardization and uniformity (41). This is an important point to consider, because 
NSCLC radiomics models could be easily confounded by patient variability (different 
treatment types, different disease stages, different demographics, etc.), image variability 
(motion management, voxel size, contrast vs. no contrast, helical vs. axial, etc.), or by 
interpretation variability (inter-operator segmentation differences, subtle differences in image 
feature extraction algorithms, etc.). Each of these sources of variability needs to be carefully 
minimized. In theory, interpretation variability can be controlled for through automated 
segmentation and feature extraction standardization. Patient variability, on the other hand, 
cannot be controlled for on data sets studied retrospectively. This is a challenge because 
training a model requires as many patient-outcome pairs as possible and this is usually at 
odds with patient uniformity. Image variability also introduces the same problem: obtaining a 
larger sample to study introduces more variability.  
To address some of these concerns, the Quantitative Imaging Biomarkers Alliance, 
organized by the Radiological Society of North America in 2007, is working to harmonize 
imaging standards across institutions and CT machine venders (42). Additionally, in a simple 
water phantom study, several CT texture features have been shown to be relatively robust to 
kVp and mAs variation (43). For more complex human data, there is a publically available 
“test-retest” dataset of 32 NSCLC patients in which each patient was scanned twice on the 
same CT machine with a short break in between (44). This dataset was utilized by Kumar et 
al. (23) to identify 39 out of 327 image features that were reproducible, non-redundant, and 
informative. Reproducibility was quantified by the concordance correlation coefficient (45) 
and is desirable to ensure imaging biomarker model fidelity and generality. Informativeness 
was quantified using the dynamic range and is important for discerning patients. Non-
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redundance was quantified by feature correlation coefficients and is desirable to increase 
model interpretability and reduce overfitting. 
Basu et al. (2012) extracted these 39 features from a separate set of 95 NSCLC 
patients, binarized patient outcomes around 2 year survival, and tested various classifiers to 
obtain an area under the curve (AUC) of 0.68 (41). However, this study is limited by 
treatment variability and imaging variability within its patient dataset. Patients received 
different types of radiation treatments and chemotherapy, and imaging was done on several 
different machines with considerable parameter variation. For example, slice thickness was 
highly variable for the images and likely limited the usefulness of RLM and COM features 
since they assume a static voxel size. Aerts et al. (2012) performed a similar survival 
prediction study on a larger data set (412 patients) and obtained an AUC of 0.70 (46, 47). 
Besides being limited by treatment variability and imaging variability, these two studies 
assumed that the reproducible feature set found by Kumar et al. (23) would also be 
reproducible on the machines used to collect their data, but the validity of this assumption is 
unclear. Therefore, to expand upon previous work in NSCLC CT radiomics, the significance 
of this project is to 1) predict NSCLC treatment outcome from patients with uniform treatment 
and imaging and 2) use public and internal NSCLC CT test-retest datasets to identify image 
features that are robust across multiple CT machines.  
1.2 Hypotheses 
1. CT image features extracted from pre-treatment NSCLC tumors can be used to 
predict tumor shrinkage in response to therapy.  
2. Using several selection metrics, a small subset of multi-machine reproducible, 
non-redundant, and informative image features can be identified for each of 
several different CT image types.  
1.3 Specific Aims 
The hypotheses will be tested through the following specific aims: 
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1. Develop MATLAB code which can access ROIs from the Pinnacle3 TPS and extract 
3D quantitative image features from an ROI’s geometry, intensity histogram, absolute 
gradient image, run-length matrices, and co-occurrence matrices.  
2. Predict NSCLC tumor shrinkage for patients treated with IMRT and PSPT using 
models based on pre-treatment CT image features.  
3. Develop a user-friendly graphical user interface program to leverage previously 
developed code by streamlining Pinnacle ROI location, verification, and image 
feature extraction. 
4. Characterize the reproducibility, non-redundance, and informativeness of CT image 
features and identify subsets of image features that are optimal under image 
acquisition protocols. 
1.4 Thesis Organization 
This thesis is intended to serve as a permanent record of the work that was 
completed to evaluate the hypotheses of the project. Chapters 2 and 3 are self-contained 
studies, each including an introduction, methods, results, discussion, and conclusions. 
These chapters each describe separate portions of the work completed for this project. 
Chapter 2 addresses specific aims 1 and 2, providing reasonably accurate 
predictions of NSCLC tumor shrinkage from pre-treatment CT images. Chapter 3 addresses 
specific aims 3 and 4, and lists relatively small image feature sets that are reproducible, non-
redundant, and informative for each of the following image types: cine 4D-CT average 
images, cine 4D-CT end-exhale images, and inspiratory breath-hold helical 3D-CT images. 
In closing, Chapter 4 is a summary of the overall research project. This section assesses the 
hypotheses, draws overall conclusions, and proposes future related research.  
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Chapter 2: NSCLC tumor shrinkage prediction using quantitative image features 
2.1 Introduction 
A goal of oncology therapies is to utilize information gained from treating previous 
patients to deliver treatment specific to the patient and disease. The current tumor node 
metastasis (TNM) staging system for non-small cell lung cancer (NSCLC) is used for this 
purpose and utilizes anatomical information such as the tumor size, location, spread, and 
lymph node involvement (6). Although this system is based on the study of over 67,000 
NSCLC cases, NSCLC patients with the same TNM staging often have very different clinical 
outcomes. To improve this, many models have been proposed which add additional non-
anatomical features to the TNM staging system. For example, the readily available features 
of age and body mass index have been shown to improve NSCLC staging (8). Others have 
used single nucleotide polymorphism genotyping to predict survival (9-11). NSCLC 
recurrence prediction from serum biomarkers has also been explored (12). However, these 
molecular assays are invasive, much less commonly obtained than age and body mass 
index, and could be sensitive to variations in institution demographics, sample collection, 
and/or analysis techniques. Moreover, molecular assays are also limited by the fact that 
many tumors are spatially and/or temporally heterogeneous (48, 49).  
CT images, on the other hand, are ubiquitous, non-invasive, and increasingly 
quantitative and standardized. They can also assess the tumor both spatially and through 
time (48). In basic quantitative CT imaging, such as the Response Evaluation Criteria in 
Solid Tumors (RECIST) guidelines, tumor response to therapy is gauged by one-
dimensional measurements of tumor size (50, 51). However, using more complex 
quantifiable image features such as the tumor heterogeneity and radiodensity can result in a 
significant prognostic improvement over RECIST (22). Other quantitative image features are 
usually statistical, model, or transform based and show similar prognostic promise (24, 27-
30). In light of these findings, the nascent field of radiomics aims to achieve automated high-
throughput extraction of various quantitative image features under the hypothesis that they 
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are related to gene expression and phenotype. Supporting this claim, Segal et al. (2007) 
showed that 28 image features could reconstruct 78% of a liver cancer gene expression 
profile (31). Additionally, it has been demonstrated that features such as the tumor image 
heterogeneity are associated with genomic heterogeneity and are correlated with increased 
treatment resistance and metastatic probability (27, 32). 
Recently, radiomics has been applied to NSCLC survival prediction. Kumar et al. 
(2012) extracted 327 3D features for 32 patients who underwent two CT imaging sessions 
spaced 15 minutes apart on the same machine (52). To assess intra-patient (test-retest) 
reproducibility, they calculated feature concordance correlation coefficients and dynamic 
ranges and determined that 39 of these 327 features were highly reproducible. Using this 
information, Basu et al. (2012) extracted these 39 features from a separate set of 95 NSCLC 
patients, binarized patient outcomes around 2 year survival, and tested various classifiers to 
obtain an area under the curve (AUC) of 0.68 (41). Aerts et al. (2012) used similar 
techniques on a larger data set (412 patients) to obtain an AUC of 0.70 (46, 47). 
There are several limitations to these studies, however. First, both used multiple CT 
machines to establish their CT data sets. At our institution we have found that quantitative 
image features vary significantly across different machines, even of the same model. Given 
the large size of the databases used in these two studies, it is likely that several machines 
were used and it is possible that their prognostic power was limited by inter-machine 
variability. Moreover, inter-machine variability could also affect the intra-patient variability. It 
is not clear that the same set of features identified by Kumar et al. (52) would be 
reproducible on other machines as was assumed by Basu et al. (41). Finally, both the work 
by Basu et al. (41) and Aerts et al. (46) have inter-patient treatment variability which could 
similarly limit the prognostic power of their models.  
In summary, although increasing patient database size is desirable to provide 
enough training inputs to create models with sufficient expressiveness, it may be 
counterproductive if it results in increased image and/or treatment heterogeneity that 
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confounds modelling. Therefore, the purpose of our study was to develop a quantitative 
image feature-derived prediction model for NSCLC volume shrinkage (a proxy for survival) 
on a set of patients with similar treatments all imaged with the same CT scanner and 
protocol.  
2.1 Materials and methods 
Data acquisition 
We obtained simulation and weekly free-breathing, non-contrast 4DCT images from 
66 patients with locally advanced, pathologically proven stage II-IIIB NSCLC. As part of a 
separate prospective trial comparing treatment modalities, these patients were randomly 
assigned treatment either by IMRT (36 patients) or protons (30 patients). The protons were 
delivered with passively scattered proton therapy with an assumed relative biological 
effectiveness (RBE) of 1.1. Both groups were treated to a 74 Gy (RBE) dose level and had 
concurrent chemotherapy. All simulation images were acquired with the same GE Medical 
Systems LightSpeed 16 machine (GE Healthcare, Milwaukee, WI) with helical scans using 
kVp = 120, mAs = 450, and a standard reconstruction convolution kernel. Axial images were 
512 x 512 pixels with voxel dimensions of 0.98 x 0.98 x 2.5 mm3.  
To minimize the effects of respiratory motion, physicians contoured the gross tumor 
volumes (GTVs) on the end-exhale (T50) phase of planning 4DCT images. These contours 
were propagated onto weekly images using an in-house demons-based deformation 
algorithm (53, 54). For each patient, the weekly GTV volume divided by the planning GTV 
volume was defined as the tumor response for a particular week.  
Although both treatment regimens lasted longer than six weeks, for logistical reasons 
some patients did not have 4DCT scans after week six. Therefore, week six was chosen as 
the “final” time point for prediction of the tumor response from the initial planning images. For 
modelling, both the IMRT and proton data sets were pooled in order to obtain a larger set of 
observations, and one patient from each group was thrown out for being a tumor response 
outlier (deviating by more than two standard deviations). Results from (55) support pooling 
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the two data sets by showing that each group had remarkably similar tumor responses (see 
Table 2.1). In fact, the p-value that the two groups’ tumor responses have equal means is 
0.733.  
Table 2.1: Week six tumor responses by treatment modality. The weekly tumor 
response is defined as the GTV volume for the week divided by the GTV volume on 
the planning image. Intensity modulated radiation therapy (IMRT) and passively 
scatted proton therapy (PSPT) patients showed remarkably similar tumor responses 
and were pooled for the purpose of modelling. 
Treatment 
Group 
 
N 
 
Mean 
 
Median 
 
Std. 
Dev. 
 
Max 
 
Min 
IMRT 36 0.83 0.85 0.19 1.39 0.47 
PSPT 30 0.81 0.81 0.19 1.45 0.46 
IMRT+PSPT 66 0.82 0.82 0.19 1.45 0.46 
 
Feature extraction 
We extracted quantitative image features from the pre-treatment planning GTVs 
using in-house software that used the following 3D feature sources: geometry, intensity 
histogram, absolute gradient image, co-occurrence matrix (COM), and run-length matrix 
(RLM).  See Table 2.2 for a complete listing of features extracted from each feature source. 
For the absolute gradient image, each voxel is defined as the difference between paired 
adjacent voxels in all three directions added in quadrature. For a given image and direction, 
the run-length matrix 	,  is defined as the number of voxel runs in the image with intensity 
	 and run length  (26). RLM features were extracted for 13 different 3D directions. For a 
given image and displacement vector ∆, a co-occurrence matrix 	,  is defined as the 
probability that two voxels separated by ∆ will have the intensity values of 	 and , 
respectively (25). COM features were extracted for six different one-voxel displacements: 
left, right, superior, inferior, anterior, and posterior. 
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Table 2.2: List of quantitative image features extracted from each planning CT image 
GTV. The RLM features were generated for 13 different 3D directions, and the COM 
features were generated for 6 different 3D displacements. 
 
 
Geometry  
 
 
Intensity 
Histogram 
 
 
Absolute  
Gradient 
 
 
Run-Length  
Matrix (RLM) 
 
 
Co-Occurrence  
Matrix (COM) 
Volume (V) 
Area (A) 
V/A Ratio 
Pruned Volume 
Pruned Area 
Pruned V/A Ratio 
Fx. Volume Pruned 
 
Mean 
Median 
Variance 
Skewness 
Kurtosis 
Minimum 
1th percentile 
10th percentile 
90th percentile 
99th percentile 
Maximum 
Entropy 
 
Mean 
Variance 
Skewness 
Kurtosis 
% Non-Zero 
 
Run Length Nonuniformity 
Grey Level Nonuniformity 
Long Run Emphasis 
Short Run Emphasis 
Fx. of Image in Runs 
 
Angular 2nd Moment 
Contrast 
Correlation 
Sum of Squares 
Inv. Diff. Moment 
Sum Average 
Sum Variance 
Sum Entropy 
Entropy 
Diff. Variance 
Diff. Entropy 
 
 
Prior to feature extraction, we pre-processed the GTV regions of interest (ROIs) by 
pruning (removing voxels below a certain Hounsfield unit [HU] cut-off). This was done to 
reduce contouring variability, remove air cavities, and better define the solid tumor. However, 
the optimal HU cut-off was not known a priori, so each unprocessed ROI gave rise to several 
variants, each of which had different HU cut-offs. Because the optimal voxel intensity bit 
depths were also unknown, each of these variants then gave rise to additional variants for 
which the gradient, RLM, and COM image bit depths were varied. Thus, for each patient’s 
ROI, many additional ROIs with different pruning and bit depths were created. Figure 2.1 
illustrates this process. For each unique HU cut-off and bit depth combination, the resulting 
ROIs were pooled from the 64 patients and features were extracted to create a feature 
matrix with each row corresponding to a patient and each column corresponding to a 
feature.  
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Figure 2.1: Region of interest (ROI) pre-processing. For each patient, the ROI was 
extracted according to physician-generated contours. Multiple pruned variants of 
these ROIs were created by removing voxels below various HU cut-offs. From each of 
these variants, additional variants were created and saved using several different bit 
depths (BD). 
 
We define a feature set as a collection of feature matrices where each feature matrix 
within the feature set was generated using a unique set of extraction parameters (e.g. HU 
cutoff and bit depths). To investigate the predictive power of various feature sources, we 
created four feature sets. Each of of the four feature sets used different feature sources and 
feature extraction parameters as indicated by Table 2.3. 
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Table 2.3: Feature set feature sources and extraction parameters. The feature set 
column denotes the name of a feature set as well as the source of features used to 
create the feature matrices that it contains (GEO = geometry, INT = intensity 
histogram, GRAD = absolute gradient image). The feature extraction parameter 
column shows the different feature extraction parameters that were used for each 
feature set (HU = Hounsfield unit, BD = bit depth). To populate the associated feature 
set, a feature matrix was generated for each unique combination. 
Feature Set Feature Extraction Parameters 
GEO + COM 
HUcutoff  = -250, -200, -150, -100, -50 
BDCOM  = 5, 6, 7, 8, 9 
GEO + RLM 
HUcutoff  = -250, -200, -150, -100, -50 
BDRLM = 5, 6, 7, 8, 9 
GEO + INT + GRAD 
HUcutoff  = -250, -225, -200,-175, -150, -125, -100, -75, -50 
BDGRAD = 4, 5, 6, 7, 8 
ALL 
HUcutoff  = -250, -200, -150, -100, -50 
BDCOM = 5, 6, 7 
BDRLM = 5, 6, 7 
BDGRAD = 5, 6, 7 
 
Modelling 
The fitness of prediction models was quantified using the mean squared error (MSE) 
between predictions and observations. The method for obtaining the MSE of a feature matrix 
 with column selection vector  using leave-one-out cross-validation is described here and 
in Figure 2.2. First, a row is omitted from a feature matrix and the remaining training 
observations are projected into z-score space. These are then projected into principal 
component (PC) space. Dimensionality reduction is achieved by removing PC dimensions 
that have trivial components for all training observations. Next, multiple linear regression is 
performed using the PC space columns indicated by the Boolean vector . Tumor responses 
are used as the regression target. The resulting model is known as the principal component 
regression (PCR) model (56).  
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Finally, the omitted row is converted into the same z-score PC space as the training 
observations and fed into the PCR model in order to obtain a tumor response prediction for 
the hidden observation. The squared difference between the predicted and observed tumor 
response is recorded. This process is repeated for each row to obtain the leave-one-out 
cross-validation MSE.  
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Figure 2.2: Principal component regression with leave-one-out cross-validation; the 
method for obtaining the mean squared error (MSE) of a feature matrix  with column 
selection vector  using leave-one-out cross-validation.  
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Optimization 
The previous section described how to obtain MSE as a function of the feature matrix 
and the column selection vector (i.e. , ). This section will describe how the simulated 
annealing principal component regression (SA-PCR) technique was used to find the  and  
which give the best , . First, a feature set from Table 2.3 was selected. For each 
feature matrix  in this feature set, a simulated annealing process (57) is performed using a 
geometric cooling function with   1  10 and   1  10. The Boolean vector  is 
randomly initialized and then allowed to evolve according to the simulated annealing process 
through  = 1,000 steps using ,  as the objective function.  
Out of all of the feature matrices in the feature set, the  and  that give the lowest 
MSE are taken to be the best  and . Since each feature matrix is generated by a unique 
set of feature extraction parameters, the best  then implies the best feature extraction 
parameters (i.e. HU cut-off and bit depths). The best  indicates which dimensions of the 
feature z-score PC space are best for multiple linear regression modeling. Together the best 
 and  define the best model. 
Because simulated annealing is stochastic, for the same input feature set the SA-
PCR algorithm may return different best MSEs for each execution. Therefore, in order to test 
the stability of the results, we repeated the entire SA-PCR process 100 times for each 
feature set in Table 2.3. 
Validation 
Even though the SA-PCR process implements leave-one-out cross-validation, 
because it considers many feature matrices and many feature z-score PC space selection 
vectors, there is a possibility that the best MSE and associated  and  that it finds are due 
to coincidence or spurious correlations.  To test for this possibility, we performed a negative 
control study. We again performed the entire SA-PCR process 100 times for each feature 
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set in Table 2.3 as was done to study the stability of the SA-PCR results. However, in this 
case, for each run the tumor response vector was randomly permuted with respect to the 
associated feature matrix (independently for each run). This obliterated any prognostic 
relationship between the feature matrix and the tumor response vector.  
2.3 Results 
Algorithm stability  
The histogram bins in Figure 2.3 indicate the number of times out of 100 runs that the 
best MSE returned by the SA-PCR algorithm fell into the indicated MSE range using the 
specified feature set.  The Experiment bars indicate the stability test results where the 
feature matrices are correctly paired with the tumor response vector. The dispersion of these 
distributions can be quantified using the coefficient of variation (CV). The GEO+COM feature 
set had  !"#$  3.77  10, the GEO+RLM feature set had  !"#$  2.32  10, the 
GEO+INT+GRAD feature set had  !"#$  4.98  10, and the ALL feature set had 
 !"#$  6.01  10

. 
These small coefficients of variation indicate that the SA-PCR algorithm is stable and 
returns similar MSEs for the same input, despite being a stochastic algorithm. Thus, if the 
SA-PCR algorithm was deployed as a part of a clinical workflow, 100 repetitions would not 
be needed in order to generate a good prediction model. A single run would suffice and 
would take approximately 18 minutes on a single core machine but is easily parallelizable 
and runs in about 1.5 minutes on our 12 core machine. 
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Figure 2.3: SA-PCR algorithm stability and validation. Histogram bins indicate the 
number of times out of 100 runs that the best MSE returned by the SA-PCR algorithm 
fell into the indicated MSE range using either a) geometric and COM features, b) 
geometric and RLM features, c) geometric, intensity histogram, and gradient features, 
or d) using all features (geometric, intensity histogram, gradient, RLM, and COM). 
Experiment indicates that the tumor response vector was correctly ordered with 
respect to the feature matrix. Negative control indicates that the tumor response 
vector was randomly permuted with respect to the feature matrix (independently for 
each run). 
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Algorithm validation 
The Negative Control bars in Figure 2.3 indicate the negative control results when 
the feature matrices are paired with independently randomly permuted tumor response 
vectors. These negative control MSE distributions are well separated from the experiment 
distributions for the GEO+INT+GRAD and ALL feature sets. However, there is an overlap 
between the experiment and negative control distributions for the GEO+COM and 
GEO+RLM feature sets. The probability of an experiment MSE being due to spurious 
correlation can be approximated by calculating the one-sided p-value of the mean MSE 
returned by experiment runs given negative control distribution. Using a normal 
approximation for the negative control distributions gives   1.09  10+  for the 
GEO+COM feature set,   4.87  10+ for the GEO+RLM feature set,   4.36  10, for 
the GEO+INT+GRAD feature set, and   5.02  10  for the ALL feature set.  
If the “good” MSEs found by the SA-PCR stability tests were due to spurious 
correlations, then the negative control runs should generate similarly “good” MSEs or even 
better MSEs (some tumor response vector permutations may be more susceptible to 
spurious correlations). However, this is not what was observed.  Figure 2.3 shows that the 
SA-PCR stability test MSEs are significantly and systematically lower than the negative 
control MSEs (p-values estimated above). This indicates that there is a valid prognostic 
relationship between the feature matrix and the tumor response vector that is not due to 
spurious correlations within the data.  
Algorithm Findings 
For each of the four feature sets listed in Table 2.3, the best  and  (i.e. the best 
model) was found using 100 repetitions of the SA-PCR method. Figure 2.4 shows these 
results graphically. The best model predictions from each feature set are displayed with the 
observed tumor response on the x-axis versus the leave-one-out predicted tumor response 
on the y-axis. Table 2.4 displays the optimal feature extraction parameters found for each 
feature set. The overall best model was found using the ALL feature set with a Hounsfield 
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unit cut-off of .250 and bit depths of 5 for the RLM, 7 for the COM, and 5 for the absolute 
gradient image.  
 
 
Figure 2.4: Model predictions. Each panel plots the observed tumor responses vs. the 
leave-one-out tumor response predictions from the best model found in 100 runs of 
the SA-PCR algorithm operating on one of the following feature sets: a) geometric and 
COM features, b) geometric and RLM features, c) geometric, intensity histogram, and 
gradient features, and d) all features. Note: tumor response = the final GTV volume 
(GTVf) divided by the initial GTV volume (GTVi); the MSE and Pearson’s r value are 
indicated for each panel; a line with slope = 1 (i.e. perfect prediction) is shown as a 
reference. 
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Table 2.4: Optimal feature extraction parameters. A bit depth of 12 was used for all 
intensity histogram derived features. 
Feature Set 
HUcutof
f  
BDRLM  BDCOM  BDGRAD  BDINT  
GEO + COM -250 - 7 - 12 
GEO + RLM -250 5 - - 12 
GEO + INT + GRAD -225 - - 5 12 
ALL -250 5 7 5 12 
 
To put the MSE values of Figure 2.4 in context, the best model found using the ALL 
feature set is shown in Figure 2.5 alongside two alternative prediction models. Figure 2.5b 
shows the predictions of the simplistic mean model where the “left out” patient is predicted to 
have a tumor response equal to the mean of all of the observed tumor responses. This gives 
an MSE of 2.51  10 which is 2.92 times larger than the best MSE found by the SA-PCR 
algorithm on the ALL feature set (Figure 2.5a). The negative control model shown in Figure 
2.5c was generated from the ALL feature set using a random permutation of the tumor 
response vector. Without the true feature-response (input-output) pairings, this model is 
unable to produce a linear trend and instead clusters predictions around the mean tumor 
response value. 
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Figure 2.5: Comparison between tumor response models. Panels show the observed 
tumor response vs. leave-one-out tumor response predictions from a) the optimal SA-
PCR model using the ALL feature set, b) the mean model (i.e. predicted response = 
mean response), and c) an SA-PCR model using the ALL feature set with a random 
permutation of the tumor responses with respect to the feature matrix. 
 
For each leave-one-out cross-validation step illustrated in Figure 2.2, PCR generates 
regression coefficients for each of the principal components indicated by . By averaging 
these coefficients across all cross-validations, the coefficient with the largest average 
absolute value can be identified. The principal component associated with this coefficient is 
then the most dominant principal component for determining the prediction. Figure 2.6 
shows the projection of such a dominant principal component into the feature z-score space 
for the best model found using the ALL feature set. From this projection it is clear that no 
particular image feature dominates the dominant principal component. That is, no single 
image feature seems to be a strong tumor response predictor; rather, it appears that the 
interaction of multiple features gives rise to the best model. 
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Figure 2.6: Projection of the dominant principal component into the original image 
feature z-score space for the best model found using the ALL feature set. 
  
2.4 Discussion 
Tumor response as a prediction outcome 
When deciding treatment options, predicting patient outcome regarding survival and 
normal tissue toxicity is paramount. However, as our patients are currently part of an 
ongoing study these data are not yet available. Therefore, tumor response was used as a 
substitute. We believe that tumor response (i.e. tumor shrinkage) is an acceptable proxy for 
patient outcome due to the current RECIST guidelines which state: 
 
“The use of tumor regression as the endpoint for phase II trials… is supported by 
years of evidence suggesting that… tumor shrinkage… demonstrates an 
improvement in overall survival or other time to event measures in randomized phase 
III studies.” (58) 
 
When the data is available, we plan to determine the ability of quantitative image 
feature models to predict normal tissue complications and survival.  
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Pooling photon and proton patients 
Although the photon and proton patients technically received different treatments, we 
believe that for the outcome of tumor response they can be approximated as receiving the 
same treatment. This can be justified from a theoretical standpoint since the GTVs of each 
modality were planned to receive exactly the same RBE-adjusted dose, and this argument is 
supported by the empirical findings of (55) (see Table 2.1). 
  As per the study’s design, the only dosimetric difference between the two treatment 
groups is for normal tissue dose. Thus, in the future, for the outcome of patient survival, 
there may be differences between the two groups arising from differences in normal tissue 
dose between the two treatment modalities. In such a scenario, pooling the two patient 
groups would not be appropriate for prediction of the alternative outcome of survival. 
Principal component regression as a model choice 
Inspection of the image feature covariance matrices showed that many features were 
highly correlated. This can make standard multiple linear regression unreliable because 
small changes in the data can cause large, erratic changes in the estimated coefficients. 
This is known as the problem of multicolinearity (59). By creating a basis space of 
orthogonal principal component vectors, PCR is a way to address this problem and also 
provides dimensionality reduction. However, (60) has shown that the principal components 
with the most variation are not always optimal for modelling. Thus, we introduced the 
simulated annealing algorithm as a method to find which principal components should be 
included for modelling.  
Reproducibility and robustness against spurious correlation 
The low coefficients of variation for the experiment distributions of Figure 2.3 
demonstrate the reproducibility of the SA-PCR algorithm on our dataset. Absent or minimal 
overlap between the experiment and negative control distributions in Figure 2.3 also 
demonstrate robustness to spurious correlations. With a p-value of 4.36  10, for the 
separation between its experiment and negative control distributions, the GEO+INT+GRAD 
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feature set results are the least likely to be due to spurious correlation. This implies that in 
cases where there are few patient observations, it may prudent to omit RLM and COM 
features for model construction and only use geometric, intensity histogram, and absolute 
image gradient features. Although this may slightly decrease the MSE compared to using all 
features, it will give a better guarantee that the model found truthfully identifies a relationship 
between the image features and the tumor shrinkage. Omitting the RLM and COM features 
would also make the parameter space easier to search since RLM and COM bit depths are 
no longer required. 
The optimal feature extraction parameters shown in Table 2.4 indicate that the 
optimal bit depth for each feature source (e.g. RLM, COM, etc.) appears to be independent 
of the other bit depths. That is, the optimal RLM bit depth found with the GEO+RLM feature 
set was the same as the optimal RLM bit depth found using the ALL feature set. This was 
also true for the COM and absolute gradient image bit depths. Thus, in the future it may be 
prudent to search for each optimal bit depth individually and then combine them when a 
model using all features is desired. As for the optimal HU cut-off, it appears to be 
approximately the same for each feature set and is always at or near the lowest HU cut-off 
that was explored. This indicates that future studies should consider lower HU cut-offs and 
also hints that the air-tissue boundary may contain important prognostic information 
(otherwise the optimal HU cut-offs would have been higher).  
Model success and applicability   
Our findings indicate that a quantitative image feature model can use existing CT 
images to successfully predict tumor shrinkage (see Figure 2.4). In fact, Figure 2.5 shows 
that, relative to the simplistic mean model, the tumor shrinkage uncertainty can be reduced 
by nearly a factor of three. This is very important because tumor shrinkage is prognostic, and 
thus our predictions are also prognostic. For example, a patient predicted to have a poor 
response to a particular treatment can be identified before the treatment begins. From here 
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he can either be labelled as high risk and watched closely or perhaps be transferred to a 
different treatment strategy.  
At the present, however, it is not known whether or not the models developed in this 
study can be applied to similar patients at other institutions. The model could be invalidated 
by different treatments, different imaging, and/or different patient demographics. We suggest 
a group of institutions work together to perform a study similar to (52) across multiple CT 
scanners to identify robust quantitative image features. Once these features are identified, 
standardized treatments and demographics could be agreed on, and robust predictive 
models for patient outcomes could be explored. 
2.5 Conclusion 
Quantitative image feature models derived from existing pre-treatment CT images 
were successfully able to predict NSCLC tumor shrinkage, an indicator of treatment efficacy 
and future survival. This supports the findings of (41) and (46) which showed that binary 
classifiers operating on quantitative image features could be used to predict survival 
outcomes for patients with NSCLC. When survival data is available for our patients we will 
develop similar classifiers and compare AUCs to their findings. Since our cohort’s imaging 
and treatment are both relatively homogenous compared to these studies, such future work 
could indicate how much imaging and treatment heterogeneity can affect the prognostic 
power of quantitative image feature models. 
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Chapter 3: Identification of multi-machine reproducible and non-redundant NSCLC CT 
image features 
3.1 Introduction 
In computed tomography (CT) imaging, non-small cell lung cancer (NSCLC) tumors 
are often described using qualitative descriptors (spiculated, cavitated, heterogeneous, 
etc.)(61, 62). However, recently there has been a move towards generating additional 
quantitative, objective features to describe these tumors (17). Traditional quantitative 
measures have included the one-dimensional tumor size, mean voxel intensity, intensity 
standard deviation, etc. (50, 58, 63). Newer quantitative measures are usually statistical, 
model, or transform based and reflect variations in tumor morphology, heterogeneity, and/or 
texture (24). Motivated by the hypothesis that these quantitative image features are related 
to gene expression and phenotype, the field of radiomics aims to achieve their automated, 
high-throughput extraction from standard of care images (23). Ganeshan et al. have shown 
that quantitative measures of NSCLC CT heterogeneity are associated with tumor stage, 
metabolism (39), hypoxia, and angiogenesis (40). Other quantitative image features have 
been applied to classify NSCLC as adenocarcinoma or squamous cell carcinoma (36), and 
lung tumor image fractal dimension has been shown to correlate with tumor stage (38) and 
can classify pulmonary nodules (37). Thus, several lines of evidence support the radiomics 
hypothesis for NSCLC.  
For NSCLC radiomics to be applied clinically, the intra- and inter-machine 
reproducibility of image features must be addressed. Towards this goal, the Quantitative 
Imaging Biomarker Alliance has created a technical committee dedicated towards multi-
vender CT scan standardization for the measurement of lung nodules (42). In a CT phantom, 
Ganeshan et al. (43) showed that quantitative measures of entropy and uniformity have 
lower coefficient of variation values than the mean intensity. For human study, public data is 
available from 32 NSCLC patients each scanned twice (15 minutes apart) using the same 
CT machine and protocols (44) (Figure 3.1). Kumar et al. (23) recently used this so-called 
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“test-retest” dataset to identify 39 out of 327 image features that were reproducible, 
informative, and non-redundant.  
The purpose of our study is to expand upon the work of Kumar et al. (23) by adding 
test-retest datasets from additional machines and image types. By studying different image 
types (cine 4D-CT end-exhale phase vs. average cine 4D-CT vs. breath-hold helical 3D-CT) 
we can determine which image type will give the most reproducible image features. By 
studying different machines we can investigate how much machine variation affects 
reproducibility. We also propose a way to integrate reproducibility and redundancy findings 
across multiple machines to identify a cross-machine reproducible and non-redundant image 
feature set.  This robust set of NSCLC image features could be useful for the development 
and validation of multi-machine and multi-institutional NSCLC radiomics models. 
 
Figure 3.1: Publically available test-retest images taken 15 minutes apart. 
 
Materials and methods 
Test-retest datasets 
We obtained non-contrast-enhanced cine 4D-CT test-retest scans from 31 patients 
with NSCLC who were imaged at the University of Texas M.D. Anderson (MDA) Cancer 
Center in Houston, TX (64). 16 of these test-retest pairs were acquired on a GE (General 
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Electric Healthcare, Milwaukee, WI) Discovery ST model machine (“M1”) and 15 were 
acquired on a GE LightSpeed RT 16 model machine (“M2”). Imaging parameters are shown 
in Table 3.1.  We also obtained breath-hold, non-contrast-enhanced helical 3D-CT test-retest 
scans from 25 patients with NSCLC who were imaged at the Memorial Sloan-Kettering 
Cancer Center in New York, NY (65). This is the dataset used by Kumar et al.(23) and is 
publically available as part of the Reference Image Database to Evaluate Therapy Response 
(RIDER) (44) collection hosted by the Cancer Imaging Archive (TCIA) at Washington 
University in Saint Louis, MO.  
The complete RIDER dataset has 32 test-retest patients and was collected with two 
machines: a GE LightSpeed 16 and a GE LightSpeed VCT 64. However, to isolate machine 
variation we omitted test-retest pairs from the GE LightSpeed VCT 64 machine; we also 
removed scans with GTVs that had image artifacts or appeared too difficult to contour 
accurately. This resulted in 25 test-retest pairs all acquired on the same machine, a GE 
LightSpeed 16 (“M3”). These scans had variable axial pixel dimensions because the field of 
view was independently set for each scan based on its scout image. Therefore, a “virtual” 
fourth machine (“M4”) was created by taking each M3 scan and performing 3D cubic spline 
interpolation to generate a new scan with the same voxel size as the MDA images.  This was 
done to test if features could be extracted more reproducibly from scans with a uniform voxel 
size.   
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Table 3.1: CT machine parameters. MDACC indicates M.D. Anderson Cancer Center; 
MSKCC, Memorial Sloan-Kettering Cancer Center.  
 Machines 
Parameter M1 M2 M3 
Test-Retest Pairs 16 15 25 
Institution MDACC MDACC MSKCC 
GE Machine Model Discovery ST LightSpeed RT 16 LightSpeed 16 
Detector Rows 8 16 16 
Scan Mode Cine 4D Cine 4D Helical 3D 
Breathing Free Free Insp. hold 
kVp 120 120 120 
Exposure Time (ms) 500 500 493 ± 42 
Tube Current (mA) 100 200 339 ± 63 
Filter Type BODY BODY BODY 
Convolution Kernel STANDARD STANDARD LUNG 
Axial Pixel Size (mm) 0.98 0.98 0.68 ± 0.10 
Slice Thickness (mm) 2.5 2.5 1.25 
Focal Spot Size (cm) 0.7 0.7 1.2 
 
Feature Extraction 
To minimize inter-operator contour variation, a single operator (the primary author) 
was responsible for contouring the 174 GTVs used in our study. All contouring was 
performed with the  Pinnacle3 TPS (treatment planning system; Philips Medical Systems, 
Andover, MA) using its slice by slice auto-contour function with a lower bound of 0 and an 
upper bound of 500 (values selected to increase automation and reproducibility). For 4D-CT 
scans, GTVs were contoured on the T50 phase (end-exhale) images and the average (AVG) 
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images. Clinical treatment plans with physician-generated GTVs were used to identify lesion 
locations. For the 3D-CT scans, lesions were located and contoured using dataset 
annotations from the TCIA website. In the interpolated dataset, the binary mask from original 
voxel size scans underwent a 3D cubic spline interpolation and thresholding to determine the 
new GTV mask. 
For quantitative image feature extraction, we developed the in-house Imaging 
Biomarker Extractor (IBEX) software package.  IBEX was developed using MATLAB 
(Mathworks Inc., Natick, MA) and has a graphical user interface which can directly access 
images and regions of interest (ROIs) from the Pinnacle3 TPS file system. Using this 
information, it can extract image features from the following 3D feature sources: geometry, 
intensity histogram, absolute gradient image, co-occurrence matrix (COM) (25), and run-
length matrix (RLM) (26).  For a complete list of features extracted, refer to Table 3.2. 
Additionally, for NSCLC GTVs it is common to remove voxels from the GTV region of 
interest that are below a certain Hounsfield unit (HU) cutoff before performing feature 
extraction (39, 40). This is thought to refine the ROI, making it more reproducible and 
focusing feature extraction on tissues other than air. IBEX allows for the specification of an 
HU cutoff to support this capability.    
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Table 3.2: Image Features Extracted with the Imaging Biomarker Extractor (IBEX) 
Software.  
 
 
Geometry  
 
 
Intensity 
Histogram 
 
 
Absolute  
Gradient 
 
 
Run-Length  
Matrix (RLM) 
 
 
Co-Occurrence  
Matrix (COM) 
Volume (V) 
Area (A) 
V/A Ratio 
Pruned Volume 
Pruned Area 
Pruned V/A Ratio 
Fx. Volume Pruned 
 
Mean 
Median 
Variance 
Skewness 
Kurtosis 
Minimum 
1th percentile 
10th percentile 
90th percentile 
99th percentile 
Maximum 
Entropy 
 
Mean 
Variance 
Skewness 
Kurtosis 
% Non-Zero 
 
Run Length Nonuniformity 
Grey Level Nonuniformity 
Long Run Emphasis 
Short Run Emphasis 
Fx. of Image in Runs 
 
Angular 2nd Moment 
Contrast 
Correlation 
Sum of Squares 
Inv. Diff. Moment 
Sum Average 
Sum Variance 
Sum Entropy 
Entropy 
Diff. Variance 
Diff. Entropy 
 
 
 
In our analysis, we used IBEX to extract image features from each GTV using the 
four 3D sources described. RLM features were extracted for 13 different 3D directions, and 
COM features were extracted for 3 different 3D displacements. For many features, the 
resulting values can vary substantially depending on the bit depth used to represent the 
image. Therefore, in order to get a representative sampling of feature values, all absolute 
gradient image, RLM, and COM features were extracted with three different image bit 
depths: 2, 6, and 10. The intensity histogram features were extracted using a bit depth of 12, 
and the geometric features are unaffected by bit depth. In total, for 11 different, equally 
spaced HU cutoffs between -1000 and 0, 328 image features were extracted for every GTV.  
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Quantifying reproducibility 
For a particular feature, let x be a vector of that feature’s values across the patients’ 
first scan. Let y  be a vector of that feature’s values across the patients’ second scan. The 
concordance correlation coefficient (CCC) (45), a commonly used measure of reproducibility 
and inter-rater reliability, is then defined as: 
2
2 2 2
( )
1 ( )x y x y
x y
CCC
σ σ µ µ
−
≡ −
+ + −
       (3.1)
 
As suggested by McBride (66), we defined reproducible features as those features 
with CCC ≥ 0.90. Like Kumar et al. (23), we also considered selecting features based on 
their dynamic ranges (DRs), but we noticed a strong overlap between the feature sets that 
passed a DR cutoff and the feature sets that passed a CCC.  Plots of CCC vs. 2DR−  were 
very linear (Figure 3.2), so we suspected an approximate relationship between the two 
metrics existed. Therefore, using reasonable assumptions (verified by our feature data 
values), we searched for an explanation. 
Figure 3.2: Feature CCC vs. 1/DR
scans. 
 
For a particular feature, starting with 
the second scans have the same means and variances (i.e. 
The CCC then simplifies: 
2 21 ( ) / 2 pCCC x y σ≈ − −  
 Define the range for the feature: 
Define the dynamic range of the feature:
Assume: ( )20,i N δδ σ
 
and y x y x
2 / δδ πσ=   
2 2
δδ σ=    
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2
 for 328 features extracted from M2 T50 test
Equation 3.1, assume that the first scans and 
x y pµ µ µ= ≡
      
max(max( ), max( )) min(min( ), min( ))f x y x y∆ ≡ −
/DR f x y≡ ∆ −    
δ δ≡ + ⇒ = − , then: 
      
      
 
-retest 
and 2 2 2x y pσ σ σ= ≡ ). 
      (3.2) 
   
(3.3) 
      (3.4) 
      (3.5) 
      (3.6) 
35 
 
If p δσ σ , then for uniform, Gaussian, Poisson, exponential, and other distributions: 
pf σ∆ ∝
          
(3.7) 
Substituting Equation 3.6 into Equation 3.2 gives: 2 21 / pCCC δσ σ− ∝   (3.8) 
Substituting Equations 3.5 and 3.7 into Equation 3.4 gives: /pDR δσ σ∝   (3.9) 
Therefore: 21 CCC DR−− ∝         (3.10) 
 
This explains the observations of Figure 3.2. It also implies that a cutoff on CCC 
implicitly implies a corresponding cutoff on DR. Therefore, to avoid redundant cutoffs, we 
chose to only use a CCC constraint since f∆ is sensitive to outliers.  
Thus, for each of the six machine / image type combinations (M1 T50, M2 T50, M1 
AVG, M2 AVG, M3, and M4), we used the CCC constraint to identify which of the 328 
features extracted were reproducible. This was done for each of the 11 HU cutoffs between -
1000 and 0. In order to find features that were reproducible across multiple machines, the 
intersection of individual machine reproducible feature sets was taken.  
To quantify how machine-sensitive feature reproducibility is, for two machines with 
identical image types, let A  be the set of reproducible features on one machine and B  be 
the set of reproducible features on the other. In terms of these variables, the Dice similarity 
coefficient (DSC) (67) and the Jaccard index (JI) (68) are defined as follows: 
 
2( , ) A BDSC A B
A B
∩
≡
+
                (3.11) 
( , ) A BJI A B
A B
∩
≡
∪
                 (3.12) 
To quantify inter-machine feature selection agreement, each of these values was 
calculated using machine M1 and machine M2 for both T50 images and AVG images. 
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Finding reproducible, non-redundant features 
Applying the CCC reproducibility constraint and taking the feature set intersection 
across multiple machines substantially reduced the total number of candidate features. 
However, many of the remaining features were strongly correlated with one another, and it 
would be useful to find a non-redundant subset of these features. Therefore, for a set of 
features F
 
that is reproducible across N machines, let ( )k iρ = concordance correlation 
coefficient for feature i  on machine k , and let ( , )kr i j be the sample Spearman’s rank 
correlation coefficient between feature i  and feature j on machine k . Next, define: 
1
1( ) ( )
N
k
k
i i
N
ρ ρ
=
= ∑
                 (3.13)
 
( , ) 1 ( , )k kd i j r i j= −
                 (3.14) 
1
1( , ) ( , )
N
k
k
d i j d i j
N =
= ∑
                (3.15)
 
Where ( )iρ is the mean CCC for feature i  across all N machines, ( , )kd i j is the 
similarity distance between features i  and j  on machine k , and ( , )d i j is the mean 
similarity distance between features i  and j  across all N  machines. 
Using these definitions, the similarity distance between all of the feature pairs of F
 
can be calculated for each machine, and the mean similarity distances between the feature 
pairs of F can be established. The features present in F
 
can then be hierarchically clustered 
based on the ( , )d i j distance function. By clustering until a threshold value is reached, 
several non-redundant, reproducible clusters can be identified. By picking the feature from 
each cluster with the highest average reproducibility across machines (Equation 3.13), a set 
of features that are non-redundant and reproducible across multiple machines can be 
identified. This process was performed for several different HU cutoffs and machine / image 
type combinations. In each case, the clustering algorithm used an average linkage function 
and an average mean similarity distance clustering threshold of 0.1.  
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3.3 Results 
Single Machine Reproducibility 
Figure 3.3 shows the percent of the 328 image features that had a certain CCC value 
or higher when no voxels are removed from the GTV prior to feature extraction. Intersections 
with CCC = 0.90 indicate the number of features that were considered reproducible. In the 
figure, the three image types track each other initially, but then diverge to have considerably 
different levels of reproducibility. The cine 4D-CT average images were the most 
reproducible and had curves that bent down the least; 90.5% of the features were 
reproducible for M1 AVG and 94.5% of the features were reproducible for M2 AVG. The cine 
4D-CT T50 scans were the next most reproducible (M1 T50 = 75.0% pass; M2 T50 = 71.0% 
pass), and the helical 3D-CT breath-hold scans had the fewest number of reproducible 
features (M3 = 61.0% pass). Images interpolated with uniform voxel sizes did not improve 
the number of reproducible features (M4 = 57.3% pass).  Figure 3.3 was generated multiple 
times using various HU cutoffs to generate Figure 3.4. In Figure 3.4, it is apparent that for all 
machines and image types, as the HU cutoff goes down the number of reproducible features 
tends to goes up. This trend implies that for maximum feature reproducibility, no HU cutoff 
should be used.  
 
Figure 3.3: Percent of GTV image features with a CCC greater than or equal to the 
indicated value. 
 
Multi-machine reproducibility 
For each of the data points in 
features. By taking the intersection of these sets we found features that were reproducible 
across multiple machines. Figure 
different multi-machine combinations. The same trend is noted: the number of multi
reproducible features increases as the HU cutoff is decreased. At an HU cutoff of 
no cutoff), for average scans, 86.3% of features were reproducible across both machines 
(M1 and M2), for T50 scans, 52.1% of features were reproducible across both machines, 
and for “single phase” scans (M1 T50, M2 T50, and M3), 42.1% of features were 
reproducible across all three machines. Exchanging M3 with M4 did not appreciably affect 
the number of multi-machine reproducible features (41.5%).
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Figure 3.4, each machine has a set of reproducible 
3.5 shows the reproducible feature percentage for several 
 
 
-machine 
-1000 (i.e. 
Figure 3.4: Percent of features that are reproducible (CCC 
numbers less than the specified HU cutoff are removed from the GTV before feature 
extraction.  
 
To investigate if feature reproducibility is machine
CCC vs. M2 CCC for both T50 and AVG scans (no HU cutoff). Poi
the vertical lines correspond to reproducible features on M1, and points falling above the 
horizontal lines correspond to reproducible features on M2. Venn diagram areas indicate the 
relative number of reproducible features that
The Dice similarity coefficients and Jaccard indices and indicate that T50 feature 
reproducibility is relatively machine
reproducibility is relatively machine
cutoffs are applied, both image types begin to show machine
cutoff of 0 gives DSC = 0.61 and JI = 0.44 for T50 images and DSC = 0.54 and 0.37 for AVG 
images. 
 
39 
 
≥ 0.90) when vox
-sensitive, Figure 3.
nts falling to the right of 
 were common or unique for the two machines. 
-sensitive (DSC = 0.71, JI = 0.55) while AVG feature 
-insensitive (DSC = 0.93, JI = 0.87). However, if HU 
-sensitivity. For example, an HU 
 
els with CT 
6 displays M1 
Figure 3.5: Percent of features that are reproducible across all of the machines 
specified given a particular HU cutoff
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Figure 3.6: M1 CCC vs. M2 CCC. Panel a) depicts the relationship for T50 scans and 
panel b) depicts the relationship for AVG scans. Venn diagrams, Dice similarity 
coefficients (DSC), and the Jaccard indices (JI) are displayed. The CCC ≥ 0.90 cutoff is 
shown for both axes. No HU cutoff was used.  
 
Reproducible, non-redundant feature sets 
Across single phase scans (M1 T50, M2 T50, and M3), 42.1% or 138 out of 328 
image features were reproducible on all machines (no HU cutoff). The cluster heat map (69) 
in Figure 3.7 shows the values of these 138 reproducible features for the 25 M3 test-retest 
pairs (50 scans). Repeated horizontal patterns present in the cluster heat map indicate that 
that there is considerable feature redundancy, especially for the RLM grey level 
nonuniformity (GLNU) features and RLM run length nonuniformity (RLNU) features.  
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Figure 3.7: Cluster heat map representation of the M3 scans using the 138 features 
that passed the reproducibility cutoff on single phase scans. No HU cutoff was used. 
Green cells correspond to a feature value above the mean, red cells correspond to 
feature values below the mean, and the color intensity indicates the deviation 
magnitude. Image features (rows) were clustered using the Pearson’s distance metric, 
and patient scans (columns) were clustered using a Euclidean distance metric. Both 
used an average linkage function. Scans are labeled such that the number indicates 
the test-retest pair; ‘A’ and ‘B’ represent scan #1 and scan #2, respectively. 
Dendrograms indicate the hierarchical relationships both between the features and 
between the scans 
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To address this, Equation 3.14 was used to quantify how redundant two features are 
on a particular machine. The distribution of feature similarity distances ( ( , )kd i j ) for different 
machines is shown in Figure 3.8 (no HU cutoff). Feature pairs with distances near zero are 
very redundant; feature pairs with distances near one are non-redundant. The different 
shape and increased number of non-redundant feature pairs for Figure 3.8b (M2 T50) 
compared to Figure 3.8a (M1 T50) indicate that feature redundancy is moderately machine-
sensitive. Similar histograms (data not shown) show different feature similarity distance 
distributions both for M1 T50 vs. M1 AVG and M2 T50 vs. M2 AVG, indicating that feature 
redundancy is also image type sensitive. In Figure 3.8c (M3 data) both the machine and 
image type are changed compared to Figure 3.8a and Figure 3.8b. Thus, its feature pair 
distance distribution appears quite different; relatively more feature pairs are either very 
redundant or very non-redundant, with fewer feature pairs in between. Figure 3.8d uses 
Equation 3.15 and shows the distribution of the mean similarity distances ( ( , )d i j ) across 
the three machines. Its final (0.9 to 1.0) distance bin is relatively empty, implying that it is 
rare for a feature to be strongly non-redundant across all three machines.  
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Figure 3.8: Panels a), b), and c) show histograms of the feature pair similarity 
distances for the 9453 feature pairs possible from the 138 features that passed the 
reproducibility cutoff for all single phase scans with no HU cutoff. Panel d) shows the 
distribution of mean feature similarity distances.  
 
Figure 3.9 shows a dendrogram generated from the hierarchical clustering of the 138 
features that were reproducible across all single phase scans (no HU cutoff).  It used the 
mean similarity distance of a feature pair as a distance function (distribution shown in Figure 
3.8d). It also used an average linkage function, so the distance between two feature clusters 
is the average mean similarity distance, and a cutoff value of 0.1 was selected to find a finite 
number of relatively non-redundant feature clusters (in this case 23).   
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Figure 3.9: Dendrogram illustrating hierarchical feature clustering using the average 
mean similarity distance between feature clusters as a distance metric. The average 
mean similarity distance between two clusters is the average of the mean similarity 
distances between the elements of each cluster (see inset). Two clusters merge 
(horizontal bar) when the average mean similarity distance between their constituent 
features becomes greater than the y-value indicated in the diagram. There are 23 
clusters at the average mean similarity distance cutoff of 0.1 (red line). Feature values 
came from the 138 features that passed the reproducibility cutoff on all single phase 
scans (no HU cutoff).  
 
This whole process (identifying multi-machine reproducible features and clustering to 
a threshold) was done for 4 different multi-machine combinations and 11 different HU 
cutoffs. All used the same 0.1 clustering threshold. The results are displayed in Figure 3.10, 
and show a similar trend to those in Figure 3.5: as the HU cutoff goes down, the number of 
non-redundant feature clusters goes up. Therefore, we used HU cutoff  .1000 and 
generated a list of reproducible, non-redundant features for each of the 4 multi-machine 
combinations in Figure 3.10. See Table 3.3. Each entry in the table is a representative 
feature from one of the reproducible, non-redundant clusters of the multi-machine 
combination indicated. For cine 4D-CT average images and for cine 4D-CT T50 images, we 
recommend columns 1 and 2, respectively.  For “single phase” mixed cine 4D
images and helical 3D-CT breath
breath-hold images we recommend column 4. 
 
Figure 3.10: Number of non
distance > 0.1) generated by hierarchically clustering features that are reproducible 
across all of the machines specified
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-hold images, we recommend column 3. For helical 3D
 
-redundant feature clusters (average mean similarity 
.  
 
-CT T50 
-CT 
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Table 3.3: Multi-machine reproducible and non-redundant feature lists. Coordinates 
indicate either a direction (RLM) or a displacement (COM); BD indicates bit depth; VA 
ratio, volume to area ratio; GEO, geometric; IHIST, intensity histogram; IGR, absolute 
gradient image; RLM, run length matrix; COM, co-occurrence matrix; p10tile, 10th 
percentile; FxR, fraction in runs; SRE, short run emphasis; LRE, long run emphasis; 
RLNU, run length nonuniformity; GLNU, grey level nonuniformity; PNonZero, 
probability non-zero. 
M1 AVG & M2 AVG 
(38 features) 
M1 T50 & M2 T50 
(28 features) 
M1 T50 & M2 T50 & M3 
(23 features) 
M3 
(33 features) 
IHIST entropy GEO VA ratio GEO VA ratio GEO volume 
IHIST kurtosis IHIST entropy GEO volume IHIST kurtosis 
IHIST max IHIST kurtosis IHIST kurtosis IHIST p10tile 
IHIST mean IHIST p10tile IHIST p10tile IHIST skewness 
IHIST min IHIST p1tile IHIST skewness IGR BD10 PNonZero 
IHIST p10tile IHIST skewness IGR BD10 Skewness IGR BD6 Mean 
IHIST p1tile IGR BD2 Variance IGR BD6 Mean RLM BD10 FxR (1,0,1) 
IHIST p99tile IGR BD6 Mean RLM BD10 LRE (1,0,0) RLM BD10 FxR (1,0,-1) 
IHIST variance RLM BD10 RLNU (0,1,0) COM BD10 AngScMom (-1,0,0) RLM BD10 FxR (-1,1,1) 
IGR BD10 Variance RLM BD10 SRE (1,0,0) COM BD10 Correlation (0,-1,0) RLM BD10 FxR (1,1,-1) 
IGR BD2 Kurtosis COM BD10 AngScMom (-1,0,0) COM BD10 Correlation (-1,0,0) RLM BD10 LRE (0,1,0) 
IGR BD2 Variance COM BD10 Correlation (-1,0,0) COM BD10 DifEntrp (-1,0,0) RLM BD10 LRE (1,0,0) 
IGR BD6 Skewness COM BD10 DifEntrp (0,-1,0) COM BD10 Entropy (-1,0,0) RLM BD10 LRE (1,1,0) 
RLM BD10 LRE (0,1,-1) COM BD10 DifEntrp (-1,0,0) COM BD10 InvDfMom (0,-1,0) RLM BD10 LRE (-1,1,0) 
RLM BD10 RLNU (0,0,1) COM BD10 Entropy (-1,0,0) COM BD10 InvDfMom (-1,0,0) RLM BD6 SRE (0,1,0) 
RLM BD2 FxR (1,1,0) COM BD10 InvDfMom (0,-1,0) COM BD10 SumEntrp (-1,0,0) RLM BD6 SRE (1,1,0) 
RLM BD2 FxR (-1,1,-1) COM BD10 InvDfMom (-1,0,0) COM BD10 SumOfSqs (0,-1,0) RLM BD6 SRE (1,1,-1) 
RLM BD2 RLNU (1,0,-1) COM BD10 SumEntrp (-1,0,0) COM BD2 SumVarnc (0,0,-1) COM BD10 AngScMom (-1,0,0) 
RLM BD2 SRE (1,1,0) COM BD10 SumOfSqs (0,-1,0) COM BD6 DifEntrp (-1,0,0) COM BD10 Correlation (0,-1,0) 
RLM BD2 SRE (-1,1,0) COM BD2 SumOfSqs (0,0,-1) COM BD6 DifVarnc (-1,0,0) COM BD10 DifEntrp (0,0,-1) 
RLM BD6 GLNU (0,0,1) COM BD2 SumVarnc (0,0,-1) COM BD6 Entropy (0,-1,0) COM BD10 DifEntrp (-1,0,0) 
COM BD10 AngScMom (0,0,-1) COM BD6 Contrast (0,0,-1) COM BD6 InvDfMom (0,0,-1) COM BD10 Entropy (0,-1,0) 
COM BD10 Correlation (0,-1,0) COM BD6 Correlation (0,0,-1) COM BD6 InvDfMom (0,-1,0) COM BD10 InvDfMom (0,0,-1) 
COM BD10 DifVarnc (-1,0,0) COM BD6 DifEntrp (0,-1,0) COM BD10 InvDfMom (0,-1,0) 
COM BD10 Entropy (0,-1,0) COM BD6 DifEntrp (-1,0,0) COM BD10 InvDfMom (-1,0,0) 
COM BD10 InvDfMom (0,-1,0) COM BD6 DifVarnc (0,-1,0) COM BD10 SumEntrp (0,0,-1) 
COM BD10 SumEntrp (0,0,-1) COM BD6 DifVarnc (-1,0,0) COM BD10 SumEntrp (-1,0,0) 
COM BD2 Contrast (0,0,-1) COM BD6 InvDfMom (0,0,-1) COM BD2 SumVarnc (0,0,-1) 
COM BD2 Contrast (-1,0,0) COM BD6 Correlation (-1,0,0) 
COM BD6 AngScMom (0,-1,0) COM BD6 Entropy (-1,0,0) 
COM BD6 DifEntrp (0,0,-1) COM BD6 InvDfMom (0,-1,0) 
COM BD6 DifEntrp (0,-1,0) COM BD6 InvDfMom (-1,0,0) 
COM BD6 DifEntrp (-1,0,0) COM BD6 SumVarnc (0,0,-1) 
COM BD6 DifVarnc (0,0,-1) 
COM BD6 DifVarnc (0,-1,0) 
COM BD6 Entropy (0,0,-1) 
COM BD6 InvDfMom (0,-1,0) 
COM BD6 InvDfMom (-1,0,0) 
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To confirm that the recommended feature sets are non-redundant, we generated a 
cluster heat map (Figure 3.11) for all single phase scans (32 M1 T50 scans, 30 M1 T50 
scans, and 50 M3 scans) using the 23 features from Table 3.3, column 3. The absence of 
repeated vertical patterns in the heat map indicates that the selected features are non-
redundant. Furthermore, blinded to the fact that test-retest pairs were present, 55 out of 56 
test-retest pairs were correctly placed adjacent to one another in the figure. This indicates 
that the selected features were sufficiently informative to accurately match and distinguish 
patients. 
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Figure 3.11: Cluster heat map representation of all scans from M1 T50, M2 T50, and 
M3 (no HU cutoff). Green cells correspond to a feature value above the mean, red cells 
correspond to feature values below the mean, and the color intensity indicates the 
deviation magnitude. For readability, orientations are reversed from Figure 3.6. Each 
of the 23 features shown had the highest average CCC from one of the 23 
independent clusters shown in Figure 3.9. Features (columns) were clustered using 
the Pearson’s distance metric, and patient scans (rows) were clustered using a 
Euclidean distance metric. Both used an average linkage function. Scans are labeled 
such that the number indicates the test-retest pair; ‘A’ and ‘B’ represent scan #1 and 
scan #2, respectively. Dendrograms indicate the hierarchical relationships between 
the features and between the scans.  
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3.4 Discussion 
Our study was strongly inspired by Kumar et al. (23), however, there are several key 
differences. We applied their techniques to several different machines and image types and 
studied how different machines and image types affected feature reproducibility and 
redundancy. We also studied feature reproducibility as a function of HU cutoff (i.e. GTV 
pruning) and omitted the feature dynamic range requirement. Additionally, we developed a 
strategy to integrate the findings to produce a multi-machine reproducible and non-
redundant feature set. We also omitted some of the patients used by Kumar et al. (23), used 
a different set of image features, and had a different semi-automated contouring process. 
These methodological differences could explain why our CCC values were relatively higher, 
leading us to chose to use a reproducibility cutoff of 0.90 instead of 0.85 (23).  
CT image type was found to strongly affect feature reproducibility (Figure 3.3, Figure 
3.4, and Figure 3.5). Features from cine 4D-CT average images were substantially more 
reproducible than those associated with T50 images, and T50 associated features were 
somewhat more reproducible than breath-hold helical 3D-CT features. This may seem 
counter-intuitive since T50 images are intended to “freeze” motion. However, because 
average images are an average of 10 image phase reconstructions, they are less 
susceptible to photon noise and various 4D-CT artifacts (70-72). As for the breath-hold CTs, 
it is difficult to draw conclusions since the machine, image type, and convolution kernel 
varied simultaneously compared to the other datasets. However, M4 did not appear to have 
better reproducibility than M3. That is, no significant reproducibility improvements were 
observed when scans were interpolated to have a uniform voxel size. If raw CT data were 
available it may have been possible to reconstruct images with a standard voxel size and 
achieve better results. 
As the HU cutoff goes down (i.e. as fewer low-intensity GTV voxels are pruned), we 
found 1) reproducibility becomes less machine-sensitive (Figure 3.6), 2) individual machine 
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reproducibility goes up (Figure 3.4), 3) multi-machine reproducibility goes up (Figure 3.5), 
and 4) the number of multi-machine, non-redundant clusters goes up (Figure 3.10). This last 
finding is particularly interesting since it implies that the low intensity voxels contain non-
redundant information. Since the vast majority of the low intensity voxels appear at the tumor 
periphery, these findings indicate that the periphery contains valuable non-redundant 
information which can be used to discriminate tumors. This is understandable, since non-
contrast-enhanced CT has limited soft tissue contrast; if the periphery is removed, there are 
fewer intensity variations to extract independent features from. Thus, we recommend against 
removing voxels based on their intensity values as a pre-processing step to feature 
extraction. This is in opposition to the NSCLC CT protocol of Ganeshan et al. (39, 40), but 
we believe that it is likely due to methodological differences. In their studies, directionally 
independent first-order statistics (e.g. entropy and uniformity) were extracted from the filtered 
2D image slice that had the largest transverse tumor length. In our work, features are 
extracted from the intensity histogram, absolute gradient image, RLM, and COM values 
evaluated over the entire unfiltered GTV. Therefore, as a caveat, we should emphasize that 
our tumor pre-processing (i.e. pruning) protocols and feature set recommendations are only 
applicable to similar datasets (non-contrast-enhanced NSCLC CT images) using similar 
image features (Table 3.2). 
One limitation of our study is that all semi-automated contouring was done by a 
single individual (the primary author). Ideally, multiple individuals could contour each GTV 
and operator sensitivity could be studied. Alternatively, one of several automated 
segmentation techniques could be used to possibly increase reproducibility (73). In the 
future it would also be useful to study the reproducibility of additional image features and the 
effect of convolution kernels. Another limitation is that all of the machines used in our study 
are GE machines. Ideally, multiple machines from various manufacturers should be tested to 
see if there are any systematic or random feature value variations between them. Finally, a 
key point to note is that our study only assessed intra-machine reproducibility. Multi-machine 
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reproducible features were defined as features that have good intra-machine reproducibility 
on multiple machines. Because patients were not test-retest imaged on multiple scanners, 
we cannot directly assess inter-machine reproducibility (i.e. agreement of feature values 
between machines). For ethical reasons, this necessitates a phantom, and there are several 
good candidates for future work. Court et al. (74) created a model of a real lung tumor using 
rapid prototyping, placed it into an anthropomorphic phantom, and moved it to match 
recorded tumor motion trajectories. This phantom would be very useful to study how motion 
affects feature reproducibility across multiple machines. In a separate application of rapid 
prototyping, another group has developed a way to independently control the CT number of 
every voxel of a phantom (75). Unlike a solid phantom, this model could be used to study 
image feature fidelity in the presence of subtle changes in voxel intensity and indistinct 
tissue boundaries.  
3.5 Conclusion 
This study integrated multiple NSCLC test-retest CT datasets to identify informative, 
non-redundant image features with high intra-machine reproducibility on multiple machines. 
Image feature quality was best for average 4D-CT images, and the tumor periphery was 
found to play an important role in tumor discrimination. Further advanced phantom studies 
are needed to investigate inter-machine image feature reproducibility. 
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Chapter 4: Discussion 
4.1 Summary and Conclusions 
Chapter 2 showed that quantitative image feature models derived from existing pre-
treatment CT images could successfully predict NSCLC tumor shrinkage, an indicator of 
treatment efficacy and future survival.  
Chapter 3 showed that image feature reproducibility and redundancy depended on 
both the CT machine and the CT image type. For each of the image types (end-exhale 4D-
CT, average 4D-CT, and helical breath-hold 3D-CT) multiple NSCLC test-retest CT datasets 
were integrated to identify informative, non-redundant image features with high intra-
machine reproducibility on multiple machines. Pruning of low intensity voxels showed that 
the tumor periphery plays an important role in tumor discrimination. Compared to end-exhale 
4D-CT and breath-hold 3D-CT, average 4D-CT derived image features showed superior 
multi-machine reproducibility and are the best candidates for clinical correlation.  
4.2 Evaluation of Hypotheses and Specific Aims 
Specific aims 1 and 2 were successfully completed by the work presented in Chapter 
2 and resulted in the confirmation of the first hypothesis: CT image features extracted from 
pre-treatment NSCLC tumors can be used to predict tumor shrinkage in response to therapy. 
 Specific aims 3 and 4 were successfully completed by the work presented in Chapter 
3 and resulted in the confirmation of the second hypothesis: various selection metrics can 
identify a small subset of “ideal” image features for each of several different CT image types.  
4.3 Future Research and Applications 
Chapter 2 supports the findings of (41) and (46) which showed that quantitative 
image features could be used to make clinically relevant predictions for NSCLC patients. As 
our survival outcome data is currently unavailable, we are unable to develop a binary 
classifier to predict survival at present. However, in the future when this data is available, we 
could develop such a model. Since our dataset had more uniform treatment and imaging, 
54 
 
comparing its AUC to their findings could indicate how important treatment uniformity and 
imaging uniformity are for accurate radiomics survival prediction. This could have important 
applications when planning future prospective radiomics studies.  
A limitation of our study in Chapter 3 is that a test-retest patient is only scanned on 
one machine. Therefore, we only have information to assess intra-machine reproducibility. 
To simultaneously assess both intra- and inter-machine reproducibility, a patient needs to be 
imaged at least twice on two machines (i.e. four total scans). This is not ethically justifiable, 
so a phantom is required. To examine how tumor motion affects inter-machine 
reproducibility, a 3D printed moveable phantom could be used (74). To how much fine tumor 
detail affects inter-machine reproducibility, another 3D printed phantom with finely controlled 
voxel CT numbers could be used (75). This later approach is a better simulation of tumor 
visual complexity, but it does not include tumor motion. One possible solution to this is to 
print test-retest image pairs directly into a CT number accurate phantom. By scanning this 
phantom on multiple machines, human test-retest scans on multiple machines could be 
simulated. Additionally, since the printed images already have motion-induced changes, this 
static phantom would allow for the simultaneous investigation of fine tumor detail and 
motion. This could be applied in future radiomics studies to find image feature sets that 
simultaneously optimize intra- and inter-machine reproducibility.  
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